Papers

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

Christine Jenkins, John Costello, Linda Hodge

Abstract

Objective To reassess the prevalence of aspirin induced asthma and other issues related to the syndrome.

Data sources Biosis, SciSearch (1990 to March 2002), Embase (1974 to March 2002), Medline (1966 to March 2002), Toxline, Derwent Drug File (1964 to March 2002), Conference Papers Index and Inside Conferences, Int'l Pharmaceutical Abstracts, Pharma-Online (1978 to March 2002).

Selection criteria Study type, patient population, and outcome measures. Review was restricted to respiratory responses to analgesics available without prescription.

Results The prevalence of aspirin induced asthma was highest when determined by oral provocation testing (adults 21%, 95% confidence interval 14% to 29%; children 5%, 0% to 14%) than by verbal history (adults 3%, 2% to 4%; children 2%, 1% to 3%). Cross sensitivity to doses of over the counter non-steroidal anti-inflammatory drugs was present in most patients with aspirin induced asthma: ibuprofen, 98%; naproxen, 100%; and diclofenac, 93%. The incidence of cross sensitivity to paracetamol among such patients was only 7%.

Conclusions Aspirin induced asthma in adults is more prevalent than previously suggested. When there is a clinical necessity to use aspirin or a non-steroidal anti-inflammatory drug and there is uncertainty about safety, oral provocation testing should be performed.

Introduction

Aspirin induced asthma is a distinct clinical syndrome affecting some asthmatic patients. It is characterised by the onset of asthma 30 minutes to three hours after the ingestion of aspirin. Although the name of the condition relates to aspirin, it is well established that affected patients are cross sensitive to all non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclo-oxygenase (COX) enzymes.¹⁻² Paracetamol (acetaminophen), however, is seldom associated with cross sensitivity in patients with aspirin induced asthma. Emerging evidence shows that paracetamol may exert at least part of its analgesic effect through a newly identified COX-3 isoenzyme, whereas aspirin induced asthma is believed to involve inhibition of COX-1.³⁻⁵

Despite a wealth of literature on aspirin induced asthma, controversy remains as to its prevalence, with published data ranging from 4% to 44%. Differences in populations studied, methods used, definitions of outcomes, and criteria for defining sensitivity reactions may all be responsible for the variations in reported rates.⁶⁻⁸ A greater understanding of aspirin induced asthma is desirable, particularly given the increasing trend for consumers to treat themselves for minor painful conditions and

the lack of association by many consumers between asthma and some analgesics. We performed a systematic review to reassess the prevalence of aspirin induced asthma in the general asthma population and to understand better the cross sensitivity of these individuals to commonly used non-prescription analgesics.

Methods

On 3 March 2002 we identified articles, in any language, with data on aspirin sensitivity among asthmatic patients and the use of paracetamol or NSAIDs. Additional articles were found through archives and the reference lists of identified articles. We excluded from the main analysis studies reporting non-respiratory responses to analgesics, such as urticaria.

Analysis of prevalence

Most of the studies recruited from asthma clinics or hospitals where patients had presented with acute exacerbations. To account for preselection bias, we subdivided the participants into three groups: group 1, all patients with asthma—with or without

Fig 1 Inclusion of studies

Table 1 Prevalence of aspirin induced asthma in adults, analysed by population and test method. Values are numbers (percentages) unless stated otherwise

Trial	Study design	Study population	Authors' definition of positive response	Oral provocation testing	Oral provocation testing and verbal history of aspirin induced asthma	Verbal history alone
Group 1: unselected asthma population*						
Delaney 1976 ¹²	Double blind, placebo controlled	Outpatients: bronchodilators and antihistamines withheld 6-12 hours before testing, corticosteroids allowed	Reduction in FEV ₁ ≥20% from baseline for up to four hours	44/230 (19.1)	118/304 (38.7)	—
Weber et al 1979 ¹⁵	Randomised, single blind, placebo controlled	Allergy and asthma clinic: no asthma drugs taken 12 hours before testing	Abnormal pulmonary function test results, including reduction in FEV ₁ >25%	15/30 (50)	—	—
Stevenson et al 1975 ¹¹	Single blind, placebo controlled	Female hospital patients with clinically obvious asthma: put on restricted diet, antihistamines omitted 48 hours before testing, bronchodilator treatment omitted six hours before testing	Reduction in peak expiratory flow >20%	31/122 (24.6)	—	—
Spector et al 1979 ¹⁴	Open challenge, patient reporting	Hospital (n=20), outpatient (n=35)	Reduction in FEV ₁ >30%	9/55 (16); incidence was higher in hospital patients than outpatients (35% v 6%)	—	8/55 (15)
Picardo et al ¹⁶	Open challenge, patient reporting	Consecutive sample: hospital (n=39), outpatient (n=35)	Reduction in FEV ₁ >30%	14/74 (19)	—	12/74 (16)
Walton and Randle 1957 ²⁶	Retrospective, medical records	Private patients visiting allergist	Bronchospasm	—	—	55/1775 (3.1)
Castillo and Picado 1986 ¹⁸	Retrospective, multicentre cohort with questionnaire follow up	Intensive care unit	Not available	—	—	36/147 (24.3); 40% in steroid dependent v 19% in non-steroid dependent asthmatic patients
Towns and Mellis 1984 ²⁵	Retrospective, medical records	Asthma clinic	Not available	—	—	24/1205 (2.0)
Fischer et al 1983 ²⁴	Retrospective, medical records	Asthma clinic	Not available	—	—	69/2580 (2.7)
Total % (95% CI)†				21.1 (13.6, 28.6)	38.7 (33.2, 44.2)	2.7 (1.6, 3.8)
Group 2: preselected population with history of aspirin induced asthma‡						
Delaney 1976 ¹²	Double blind, placebo controlled	Outpatients: bronchodilators and antihistamines withheld 6-12 hours before testing; corticosteroids allowed	Reduction in FEV ₁ ≥20% from baseline for up to four hours	29/59 (49)	—	—
Webber et al 1979 ¹⁵	Randomised, single blind, placebo controlled	Allergy and asthma clinic: no asthma drugs taken 12 hours before testing	Abnormal pulmonary function test results, including reduction in FEV ₁ >25%	13/15 (87)	—	—
McDonald et al 1972 ¹⁰	Single blind, controlled	Allergy clinic	Rapid reduction in FEV ₁ ≥ 20%	41/87 (47)	—	—
Vally et al 2002 ⁸	Single blind, controlled	Allergy and asthma clinic: stable asthma, usual maintenance drug allowed	Rapid reduction in FEV ₁ >50%	8/42 (19)	22/282 (8)*	—
Stenius and Lemola 1976 ¹³	Single blind, controlled	Allergy and asthma clinic: first 12 patients had asthma drugs withdrawn, remainder took usual drugs 1-2 hours before attending clinic	Reduction in FEV ₁ ≥25% from baseline	13/39 (34)	20/45 (44)	—
Nizankowska et al 2000 ⁹	Single blind, controlled retrospective analysis	Allergy and asthma clinic patients	Rapid reduction in FEV ₁ >50%	7/79 (9)	—	—
Falliers 1983 ¹⁷	Open challenge	Outpatients	FEV ₁ >35%	9/11 (82)	—	—
Kwong and Feinstein 1986 ⁶	Three population surveys	Survey 1: metropolitan community, hospital cohort (n=150); survey 2: metropolitan community, members of asthma foundation of Western Australia (n=366); survey 3: rural community of Western Australia (n=1298; asthmatic patients n=128)	Not available	—	—	17/150 (11.3); 48/366 (13.1); 14/128 (10.9)
Total (95% CI)†				29.5 (18.2 to 40.8)	9.4 (4.7 to 14.1)	12.2 (8.0 to 16.4)
Group 3: pre-selected population with no history of sensitivity‡						
Delaney 1976 ¹²	Double blind, placebo controlled	Outpatients: bronchodilators and antihistamines withheld 6-12 hours before testing; corticosteroids allowed	Reduction in FEV ₁ ≥20% from baseline for up to 4 hours	15/171 (8.7)	—	—
Weber et al ¹⁵	Randomised, single blind, placebo controlled	Allergy and asthma clinic: no asthma drugs taken 12 hours before testing.	Abnormal pulmonary function test results, including reduction in FEV ₁ >25%	2/15 (13)	—	—
Total (95% CI)¶				9.0 (3.7 to 14.3)	—	—

FEV₁=forced expiratory volume in one second.

*Includes patients with and without a history of aspirin induced asthma and with and without markers of increased risk or likelihood of aspirin induced asthma. †Included patients with history of aspirin induced asthma or with markers of increased risk or likelihood of aspirin induced asthma. ‡Included patients without a history of aspirin induced asthma or without markers of increased risk or likelihood of aspirin induced asthma. §Authors noted this to be underestimation and said real prevalence in population to would be 10-16%. ¶Calculated from pooling incidence rates in individual studies.

a history of aspirin induced asthma and with or without markers of an increased risk or likelihood of the syndrome; group 2, patients preselected on the basis that they had either a reliable history of aspirin induced asthma or markers of an increased risk or likelihood of the syndrome; and group 3, patients with no markers of an increased risk or likelihood of aspirin induced asthma.

The primary outcome was to determine whether the ingestion of aspirin triggered an asthmatic response. For this reason we included in the main analysis only studies in which patients underwent provocation challenges. Our analysis defined a positive aspirin induced asthma response as a 20% or more reduction in forced expiratory volume in one second within three or four hours of the challenge, as recently described.⁹

Owing to the potential for severe reactions in patients with aspirin induced asthma, provocation challenges in patients with an unequivocal history of aspirin sensitivity is deemed unethical. In view of this, many authors had combined the results from such patients with the number of patients showing a positive reaction to provocation challenge; we included such studies in a subanalysis.

The use of history alone for determining aspirin sensitivity among asthmatic patients has underestimated and overestimated prevalence. Therefore we also conducted a subanalysis of papers in which history was the only means of determining aspirin sensitivity.

Analysis of incidence of cross sensitivity to NSAIDs or paracetamol

In the analysis of cross sensitivity we included only level 1 studies representing properly controlled, randomised, and single blinded or double blinded clinical trials. The primary outcome was to determine whether the ingestion of NSAIDs (specifically ibuprofen, naproxen, and diclofenac) or paracetamol triggered an asthmatic response in patients who had been positively identified

as having aspirin induced asthma by oral provocation testing, history, or both. Studies were only included for analysis if cross sensitivity to NSAIDs or paracetamol was determined by provocation challenge.

Statistical analysis

Using a weighted average of the incidence rates from individual studies, we calculated pooled incidence rates and 95% confidence intervals. The reciprocal of the variance in each study was calculated for weighting.

Results

Prevalence in adults

A total of 66 papers were identified that gave the prevalence for aspirin induced asthma. Only 21 (15 in adults and six in children) were eligible for inclusion in our analysis (fig 1).^{8 10–29} Although a double blind trial would produce more robust data, this is not the usual method employed for studies of aspirin induced asthma owing to the high risk of life threatening reactions. Only four of the trials were double blind.

The pooled incidence of aspirin induced asthma was 21% (95% confidence interval 14% to 29%), regardless of whether the patients had a history of aspirin induced asthma or markers for an increased risk of the syndrome (table 1). Prevalence of aspirin induced asthma also seemed to depend on the method used to determine it, with history alone resulting in a much lower prevalence (2.7%). Four of the studies in adults gave data on the number of patients reacting to different doses of aspirin.^{12 14 15 17} Around half (57/113) of those who had positive reactions, did so at low doses of aspirin (≥ 80 mg), indicating that they were highly sensitive.

Prevalence in children

Aspirin induced asthma has been considered rare in children, yet we found that although it is less common in children than in

Table 2 Prevalence of aspirin induced asthma in children, analysed by population and test method. Values are numbers (percentages) unless stated otherwise

Trial	Study design	Mean age (years)	Study population	Authors' definition of positive response	Oral provocation testing	Oral provocation testing and verbal history of aspirin induced asthma	Verbal history alone
Group 1: Unselected asthma population*:							
Marquett et al 1992 ²⁰	Randomised, double blind, placebo controlled	13.5	Asthma clinic: moderately severe asthma	Reduction in FEV ₁ >2 SD from mean placebo response (all positives were >20% reduction in FEV ₁)	5/54 (9)	7/56 (13)	—
Rachelefsky et al 1975 ²¹	Open challenge	9.6	Outpatients	Reduction in peak expiratory flow rate $\geq 20\%$	0/32 (0)	—	—
Schuhl and Pereyra 1979 ²³	Single blind	9.0	Asthma clinic: chronic asthma	Reduction in peak expiratory flow rate and FEV ₁ $\geq 20\%$	6/29 (20.7)	—	—
Pearson 1963 ²⁷	Medical records	Range 6–16	Allergy and asthma clinic	Not available	—	—	25/1298 (1.9)
Total (95% CI)†	—	—	—	—	5.0 (0 to 14.0)‡	12.5 (3.8 to 21.2)	1.9 (1.2 to 2.6)
Group 3: Preselected population with no history of sensitivity§:							
Vedanthan et al 1997 ²²	Double blind, placebo controlled	12.5	Outpatients, chronic asthma (severity varied). All drugs discontinued 12 hours before testing	Reduction in FEV ₁ >20%	3/25 (12)	—	—
Milosevic 1990 ¹⁹	Double blind, placebo controlled	13.6	Allergy clinic	Reduction in FEV ₁ $\geq 30\%$ from baseline for up to four hours	9/50 (18)	—	—
Total (95% CI)†	—	—	—	—	15.5 (4.2 to 26.8)	—	—

FEV₁=forced expiratory volume in one second.

No studies found for preselected population with a history of aspirin induced asthma or with markers of increased risk or likelihood of aspirin induced asthma (group 2).

*Includes patients with and without history of aspirin induced asthma and with and without markers of increased risk or likelihood of aspirin induced asthma.

†Calculated from pooling incidence rate in individual studies.

‡Lower bound truncated at 0.

§Includes patients without history of aspirin induced asthma or without markers of increased risk or likelihood of aspirin induced asthma.

Table 3 Incidence of cross sensitivity to NSAIDs among patients with aspirin induced asthma

Trial	Study design	Age (years)	Study population	Authors' definition of positive response	Maximum challenge dose (mg)	Subjects tested	Positive outcome	Incidence (%)	Sensitivity previously proved by challenge
Ibuprofen:									
Chafee and Settipane 1974 ²⁸	Double blind, placebo controlled	16-60	Allergy and clinical immunology department	Reduction in peak expiratory flow >15% (positive reactions ranged from 19-68%)	300	18	18	100	Yes
Szczeklik et al 1977 ¹	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in peak expiratory flow >25% with no symptoms	400	31	30	97	Yes
Total (95% CI)*	—	Not available	—	—	Not available	—	—	98 (90 to 100)†	—
Naproxen:									
Szczeklik et al 1977 ¹	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in peak expiratory flow >25% with no symptoms	100	11	11	100	Yes
Falliers 1973 ²⁹	Double blind, placebo controlled	Mean 39	Allergy and clinical immunology department	Reduction in peak expiratory flow >20% up to four hours after dose	80	11	11	100	Yes
Total (95% CI)*	—	—	—	—	Not available	—	—	100 (83 to 100)†	—
Diclofenac:									
Szczeklik et al 1977 ¹	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in peak expiratory flow >25% with no symptoms	40	14	12	86	Yes
Falliers 1973 ²⁹	Double blind, placebo controlled	Mean 39	Allergy and clinical immunology department	Reduction in peak expiratory flow >20% up to four hours after dose	25	11	11	100	Yes
Total (95% CI)*	—	Not available	—	—	Not available	—	—	93 (76 to 100)†	—

*Calculated from pooling incidence rate in individual studies.
†Upper bound truncated at 100.

adults, prevalence is still around 5% (0% to 14%) when children are subject to oral provocation testing (table 2).^{21 23 25} Although only one of the studies was a double blind, randomised controlled trial, it accounted for almost half of the patients in our analysis.²¹ As with adults, the use of history alone gave a lower estimate of prevalence (2%, 1% to 3%) than determined by oral provocation testing.

Incidence of cross sensitivity

Over the counter NSAIDs

Ten studies reported the incidence of cross sensitivity to three commonly used NSAIDs (ibuprofen, naproxen, diclofenac). Only three of these were level 1 studies eligible for inclusion.^{1 30 31} Based on these, the incidence of cross sensitivity was: ≤400 mg ibuprofen, 98% (95% CI 90% to 100%); ≤100 mg naproxen, 100% (83% to 100); and ≤40 mg diclofenac, 93% (76% to 100%; table 3).^{1 30 31}

Cross sensitivity to paracetamol

Each article on cross sensitivity to paracetamol was classified according to its methods. Ten of 52 identified papers were of level 1 studies.^{1 12 14 17 24 32-36} Table 4 summarises the data for these

studies, except for one in which the authors report the number of oral provocation tests and reactions but not the number of patients with a positive reaction.³⁶ Of 268 adults and children with aspirin induced asthma who underwent oral challenge, only 32 had a positive respiratory reaction to paracetamol (pooled incidence 7%, 0% to 16%).

Discussion

The prevalence of aspirin induced asthma is 21% for adults and 5% for children according to our systematic review. Our review is, however, limited by the retrospective nature of the analysis and the heterogeneity of the patient population. We were unable to attain the clinical status of all the patients, there was a lack of uniformity with the challenge tests, and some studies included only a small number of patients. Clinical heterogeneity was overcome by analysing different patient populations separately, and the findings are strengthened by the distinction between adults and children and the types of testing involved (oral provocation testing, patient history, questionnaire). Prospective studies in the general asthma population—correlating questionnaire responses

Table 4 Incidence of cross sensitivity to paracetamol among patients with aspirin induced asthma

Trial	Study design	Age (years)	Study population	Authors' definition of positive response	Maximum challenge dose (mg)	No of participants tested	Positive outcome	Incidence (%)	Sensitivity previously proved by challenge
Settipane et al 1995 ³³	Single blind, controlled	Mean 48.3	Allergy office	Reduction in FEV ₁ >20%	500	32	5	16	No
McDonald et al 1972 ¹⁰	Single blind, controlled	16-73	Allergy clinic	Rapid reduction in FEV ₁	1000	42	10	24	No
Weber et al 1979 ¹⁵	Randomised, single blind, placebo controlled	25-70	Allergy and asthma clinic	Abnormal results for pulmonary function tests, including reduction in FEV ₁ >25%	1000	15	0	0	Yes
Szczeklik et al 1976 ³⁰	Single blind, placebo controlled	Mean 27.2	Not specified	Reduction in FEV ₁ >20%	500	8	0	0	Yes
Szczeklik et al 1977 ³¹	Single blind, placebo controlled	20-75	Allergy clinic	Reduction in FEV ₁ >20%	1500	50	11*	22	Yes
Delaney 1976 ¹²	Double blind, placebo controlled	14-72	Outpatients	Reduction in FEV ₁ >20% from baseline for up to four hours	650	69	2	3	Yes
Szczeklik et al 1977 ¹	Double blind, placebo controlled	16-68	Allergy and clinical immunology department	Reduction in peak expiratory flow 16-25% and clinical symptoms of bronchial obstruction or reduction in peak expiratory flow >25% with no symptoms	600	49	3	6	Yes
Vedanthan et al 1997 ²²	Double blind, placebo controlled	8-18	Outpatients	Reduction in FEV ₁ >20%	600	3	1	33	Yes
Total (95% CI)†‡		Not available			Not available			6.5 (0 to 16.4)§	

FEV₁=forced expiratory flow in one second.

*Eight patients reacted to 1000mg or 1500mg and three reacted to 1500 mg only.

†Cumulative dose over four hours.

‡Calculated from pooling incidence rate in individual studies.

§Lower bound truncated at 0.

with the results of provocation challenge—are warranted to confirm the prevalence of the data we have derived.

Our value for the prevalence of aspirin induced asthma in adult asthmatic patients is higher than the 10% reported in recent reviews.^{7, 37} Methods and patient bias provide one explanation for this, since studies assessing patient history only resulted in lower estimates than those based on oral provocation testing. It is not surprising that asthmatic patients often do not report sensitivity to aspirin when questioned because many are unaware of this syndrome and do not associate the use of a pain reliever with an asthma attack. Indeed, 15% of asthmatic patients evaluated during a multicentre study spanning 10 European countries only became aware of their intolerance after provocation testing.³⁸ Under-diagnosis of the syndrome may be due to the lack of routine testing by aspirin challenge in asthmatic patients who do not report a positive history of aspirin sensitivity.³⁸

Analyses based on the use of a questionnaire resulted in a higher number of positive results than did retrospective analyses of medical records. Prevalence rates of 11-24% were given in the four studies using questionnaires,^{8, 16, 18, 20} whereas rates of 2-3% were obtained from the three studies relying on medical records.^{26, 28} One explanation for this finding is that questionnaires are usually deployed within a set time frame and by a limited number of people, whereas medical records are likely to be completed by a larger number of different healthcare professionals—the absence of a recording of aspirin induced asthma does not necessarily mean that it was not present. Retrospective analysis of medical records is therefore an insensitive means of detecting aspirin induced asthma.

Cross sensitivity to NSAIDs occurred in most of the patients with aspirin induced asthma. In contrast, the pooled incidence of cross sensitivity to paracetamol among patients with the syndrome was only 7%. Based on these data, less than 2% of

asthmatic patients are likely to react to both paracetamol and aspirin. The available data indicate that patients who are highly sensitive to aspirin are more likely to be sensitive to paracetamol than those requiring higher doses of aspirin to elicit a response. The authors of one study pointed out that their patients were highly sensitive to aspirin—the mean provoking dose was only 47 mg of aspirin, compared with 1227 mg of paracetamol.³³ They also correlated aspirin dose and frequency of cross reactivity to paracetamol (fig 2), commenting that when the aspirin dose provoking a 20% reduction in forced expiratory volume in one second was 30 mg, 83% (5/6) of patients reacted to paracetamol, but when the dose was 150 mg, none (0/4) of the patients reacted to paracetamol. This study was also used to compare the severity of paracetamol induced bronchoconstriction with corresponding reactions to aspirin in the same patients.³³ Although there was no significant difference in the magnitude of the

Fig 2 Relation between aspirin provoking dose and frequency of cross sensitivity to paracetamol (reproduced from Settipane et al 1995³³ with permission of Mosby)

Fig 3 Duration of aspirin induced and paracetamol induced bronchospastic reactions (reproduced from Settiple et al 1995³³ with permission of Mosby)

reduction in forced expiratory volume in one second with either product, the reaction to paracetamol was significantly shorter than that to aspirin (fig 3) and significantly milder, as shown by the mean number of nebuliser treatments required by the patients reacting to paracetamol (1.2 v 2.6, P=0.035).

The continuing recommendation of paracetamol as the analgesic and antipyretic of first choice for patients with asthma seems warranted given the relatively low incidence of sensitivity. The new generation of COX-2 specific analgesics may also be safer than NSAIDs and aspirin in asthmatic patients, but further experience with these compounds is required. Based on this conclusion, we have simplified guidelines for the use of analgesics in asthmatic patients (table 5). Where history neither supports nor excludes aspirin induced asthma, and aspirin or NSAIDs are clinically indicated, formal provocation testing is warranted, but because of the risk of severe bronchoconstriction this must be conducted by specialised staff with facilities for emergency resuscitation.

We found that a significant proportion of asthmatic patients are sensitive to aspirin. Many may be unaware of their sensitivity because either they have never taken aspirin or they developed aspirin induced asthma in adulthood after years of apparent tolerance. Since aspirin and NSAIDs are often self prescribed, patients diagnosed with asthma should be alerted to the possibility of aspirin induced asthma by their healthcare professional. Our data justifies the need to include simple, standardised warnings on packs of aspirin and NSAIDs, alerting asthmatic patients to the potential risks.

Table 5 Guidelines for use of analgesics in asthmatic patients

Patient characteristics	Recommendation
Anyone positively identified with aspirin induced asthma; or anyone who has ever experienced an asthmatic reaction to aspirin or NSAIDs (such as ibuprofen, diclofenac, naproxen sodium); or anyone with high risk features of aspirin induced asthma (severe asthma symptoms, nasal polyps, urticaria, or chronic rhinitis)	Patient should avoid all products that contain aspirin or NSAIDs indefinitely; paracetamol should be recommended, unless contraindicated
Younger than 40 years of age, or; have not used aspirin or an NSAID recently without incident	Aspirin induced asthma may develop late in life, so patients should be informed of risks of aspirin and NSAIDs, and paracetamol should be recommended, unless contraindicated. If NSAIDs are necessary, the first dose may be taken under medical supervision
All other asthmatic patients	Any analgesic may be considered. If patients experience any respiratory reactions in response to therapy they should be advised to stop treatment and visit a doctor

What is already known on this topic

Aspirin induced asthma is a distinct syndrome that is potentially life threatening

The prevalence and cross reactivity to other analgesics has been difficult to assess due to differences in trial methods

Asthmatic patients sensitive to aspirin are usually cross reactive to NSAIDs but seldom react to paracetamol

What this study adds

Aspirin induced asthma is more prevalent than previously suggested

Less than 2% of asthmatic patients are sensitive to both aspirin and paracetamol; reactions to paracetamol tend to be less severe

Contributors: All authors conceived and initiated this review. CJ performed the analysis and drafted the paper; she will act as guarantor for the paper. JC interpreted the results and helped with writing. LH helped with the research, interpretation, and writing.

Funding: CJ and LH are clinicians working partly in public hospital and private practice and in a research institute that receives funding from government, bequests, and many industry sources. Neither is directly funded by any manufacturer of non-steroidal anti-inflammatory drugs or paracetamol.

Competing interests: CJ has received payment from GlaxoSmithKline Consumer Healthcare Australia, the manufacturer of Panadol (paracetamol), for speaking at a conference. JC serves as a consultant on the Global Analgesics Advisory Board, which is funded by GlaxoSmithKline Consumer Healthcare.

Ethical approval: None required.

- 1 Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. *J Allergy Clin Immunol* 1977;60:276-84.
- 2 Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. *J Allergy Clin Immunol* 1984;74:617-22.
- 3 Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci USA* 2002;99:13926-31.
- 4 Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? *Lancet* 2003;361:981-2.
- 5 Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. *J Allergy Clin Immunol* 2001;108:47-51.
- 6 Kwok CK, Feinstein AR. Rates of sensitivity reactions to aspirin: problems in interpreting the data. *Clin Pharmacol Ther* 1986;40:494-505.
- 7 Levy S, Volans G. The use of analgesics in patients with asthma. *Drug Safety* 2001;24:829-41.
- 8 Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. *Thorax* 2002;57:569-74.
- 9 Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. *Eur Respir J* 2000;15:863-9.
- 10 McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma. Detection by oral challenge. *J Allergy Clin Immunol* 1972;50:198-207.
- 11 Stevenson DD, Mathison DA, Tan EM, Vaughan JH. Provoking factors in bronchial asthma. *Arch Intern Med* 1975;135:777-83.
- 12 Delaney JC. The diagnosis of aspirin idiosyncrasy by analgesic challenge. *Clin Allergy* 1976;6:177-81.
- 13 Stenius BSM, Lemola M. Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. *Clin Allergy* 1976;6:119-29.
- 14 Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. *J Allergy Clin Immunol* 1979;64:500-6.
- 15 Weber RW, Hoffman M, Raine DAJ, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. *J Allergy Clin Immunol* 1979;64:32-7.
- 16 Picado C, Castillo JA, Vennera MC, Gistau C, Burgos F, Agusti A. Aspirin intolerance: relationship with severity of clinical characteristics of asthma (abstract). *Eur J Respir Dis* 1982;63:226.
- 17 Falliers CJ. Acetaminophen and aspirin challenges in subgroups of asthmatics. *J Asthma* 1983;20:39-49.
- 18 Castillo J, Picado C. Prevalence of aspirin intolerance in asthmatics treated in a hospital. *Respiration* 1986;50:153-7.
- 19 Milosevic D. Intoleranz und allergie gegen analgetika. *Allergologie Jahrgang* 1990;13:205-9.

- 20 Marquette CH, Saulnier F, Leroy O, Wallaert B, Chopin C, Demarcq JM, et al. Long-term prognosis of near-fatal asthma: a 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. *Am Rev Respir Dis* 1992;146:76-81.
- 21 Rachelefsky GS, Coulson A, Siegel SC, Stiehm ER. Aspirin intolerance in chronic childhood asthma: detected by oral challenge. *Pediatrics* 1975;56:443-8.
- 22 Vedanthan PK, Menon MM, Bell TD, Bergin D. Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma. *J Allergy Clin Immunol* 1997;60:8-13.
- 23 Schuhl JF, Pereyra JG. Oral acetylsalicylic acid (aspirin) challenge in asthmatic children. *Clin Allergy* 1979;9:83-8.
- 24 Fischer TJ, Guilfoile TD, Kesarwala HH, Winant JGJ, Kearns GL, Gartside PS, et al. Adverse pulmonary responses to aspirin and acetaminophen in chronic childhood asthma. *Pediatrics* 1983;71:313-8.
- 25 Towns SJ, Mellis CM. Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma. *Pediatrics* 1984;73:631-7.
- 26 Walton CHA, Randle DL. Aspirin allergy. *Can Med Assoc J* 1957;76:1016-8.
- 27 Pearson RSB. Hypersensitivity to aspirin. In: Dixon A, Martin KB, eds. *Salicylates: an international symposium*. London: Churchill, 1963:170-3.
- 28 Chafee FH, Settipane GA. Aspirin intolerance I. Frequency in an allergic population. *J Allergy Clin Immunol* 1974;53:193-9.
- 29 Falliers CJ. Aspirin and subtypes of asthma: risk factor analysis. *J Allergy Clin Immunol* 1973;52:141-7.
- 30 Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G, Zmuda A. Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymatic preparations. *J Allergy Clin Immunol* 1976;58:10-8.
- 31 Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G, Pieton R. Asthmatic attacks induced in aspirin-sensitive patients by diclofenac and naproxen. *BMJ* 1977;2:231-2.
- 32 Quiralte J. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. *J Allergy Clin Immunol* 1996;98:678-85.
- 33 Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. *J Allergy Clin Immunol* 1995;96:480-5.
- 34 Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. *BMJ* 1975;1:67-9.
- 35 Barles PG, Duce GF, Portillo OJ, Perez AJ, Escuer AJ. Adverse reaction of acetaminophen as an alternative analgesic in AAS triad. *Allergol Immunopathol (Madr)* 1988;16:321-5.
- 36 Ispano M, Fontana A, Scibilia J, Ortolani C. Oral challenge with alternative nonsteroidal antiinflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these agents. *Drugs* 1993;46:253-6.
- 37 Szczeklik A, Sanak M. Molecular mechanisms in aspirin-induced asthma. *Allergy Clin Immunol Int* 2000;12:171-6.
- 38 Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. *Eur Respir J* 2000;16:432-6.

(Accepted 14 November 2003)

bmj.com 2004;328:434

Woolcock Institute of Medical Research, Royal Prince Alfred Hospital,
Camperdown, NSW 2050, Australia
Christine Jenkins *head, asthma group*

King's College Hospital, London SE5 9RS
John Costello *clinical director of medicine*

Asthma Centre, Royal Prince Alfred Hospital
Linda Hodge *dietitian*

Correspondence to: C Jenkins, Suite 702, 26 Ridge Street, North Sydney, NSW 2060, Australia crj@med.usyd.edu.au